Start
Features
Free trial / FAQ

Researchers
Physicians
Pharmacists
Ecotrophologists
Product Managers
in Health Industries

Loading…

Medical Research Finder

Legal Notice
Privacy
Terms of Use

meRfi® Microbiome - The Digital Gut Microbiome Reference (incl. AI Chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

meRfi® AI Chat

Doxorubicin & Soft Tissue Sarcoma (STS)

Welcome to meRfi Microbiome!

Please register to continue your trial period!

meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

(Login)

Navigation

Regulatory status

In the context of Doxorubicin & Soft Tissue Sarcoma (STS), doxorubicin is approved by both the FDA and the EMA for Soft Tissue Sarcoma (STS), usually for advanced or metastatic disease (2)

Clinical data

Doxorubicin is a standard of care in patients with advanced, inoperable soft tissue sarcoma (STS) (1)

References

(1) Grünwald et al. 2020 JCO 38: 3555–3564
(2) [Drugs Approved for Soft Tissue Sarcoma - NCI](https://www.cancer.gov/about-cancer/trea…

References (Sources)

Limitations in Clinical Trials Leading to Anticancer Drug Approvals by the US Food and Drug Administration
Hilal et al. 2020 JAMA Intern. Med. 180: 1108
Randomized Comparison of Pazopanib and Doxorubicin as First-Line Treatment in Patients With Metastatic Soft Tissue Sarcoma Age 60 Years or Older: Results of a German Intergroup Study
Grünwald et al. 2020 JCO 38: 3555–3564
Uncertainties that threaten the benefit/risk Balance in Early Treatment Lines for Advanced or Metastatic Soft Tissue Sarcoma
Reichardt 2021

AI Chat

7/1/2026

Chat with our artificial intelligence:

Start chat!